Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
Objective This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Methods Following overnight fasting for 10 h, a single 50 mg enteric-coated tablet...
Gespeichert in:
Veröffentlicht in: | Drugs in R&D 2016-03, Vol.16 (1), p.45-52 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 52 |
---|---|
container_issue | 1 |
container_start_page | 45 |
container_title | Drugs in R&D |
container_volume | 16 |
creator | Falchook, Gerald S. Zhou, Xiaofei Venkatakrishnan, Karthik Kurzrock, Razelle Mahalingam, Devalingam Goldman, Jonathan W. Jung, JungAh Ullmann, Claudio Dansky Milch, Catherine Rosen, Lee S. Sarantopoulos, John |
description | Objective
This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Methods
Following overnight fasting for 10 h, a single 50 mg enteric-coated tablet (ECT) of alisertib was administered under either fasted (alisertib with 240 mL of water) or fed (high-fat meal consumed 30 min before receiving alisertib with 240 mL of water) conditions using a two-cycle, two-way crossover design. Patients on both arms were not allowed food for 4 h post-dose. Water was allowed as desired, except for 1 h before and after alisertib administration.
Results
Twenty-four patients were enrolled and 14 patients were PK-evaluable (ten patients were not PK-evaluable due to insufficient data). Following a single oral dose of alisertib, median
t
max
was 6 h and 3 h under fed and fasted conditions, respectively. The geometric mean ratio of AUC
inf
(fed- vs. fasted-state dosing) was 0.94 [90 % confidence interval (CI) 0.68–1.32]. The geometric mean
C
max
under fed conditions was 84 % of that under fasted conditions (90 % CI 66–106). Alisertib was generally well-tolerated; most common drug-related grade 3/4 adverse events included neutropenia (50 %), leukopenia (38 %), and thrombocytopenia (21 %).
Conclusions
Systemic exposures achieved following a single 50 mg dose of alisertib administered as an ECT formulation after a high-fat meal are similar to those observed in the fasted state. Alisertib 50 mg ECT can be administered without regard for food.
ClinicalTrials.gov Identifier
NCT00962091. |
doi_str_mv | 10.1007/s40268-015-0114-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4767718</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4243637001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-1a4129a3e2c8ff00a6615baf5849cb2c84bb32cd18be1afbee6057acb4704a9b3</originalsourceid><addsrcrecordid>eNp1kc9uFSEUxidGY2v1AdwYEjd1MQoz_JuNyaRptfGqTaxrAgzcoc5AC8w1voZPLOOtTTVxQSDn-52PA19VPUfwNYKQvUkYNpTXEJGyEK75g-oQIdbVtIPo4e8zrgnn9KB6ktIVhBC1lD-uDhpKeUcoPax-nlprdAbBgrMQBhA8yKMBF6OMs9Thm_MmO51Wfa2f-51J2W1ldsHLCfRLDFGCHnxwXqZVH51yOUTQTy6ZmJ0Cxx83n3jTslfAeXBROo3PCXx3eQT9sJNemwF8CZMbwOUyh5ieVo-snJJ5drsfVV_PTi9P3tebz-_OT_pNrTGDuUYSo6aTrWk0txZCSSkiSlrCcadVKWKl2kYPiCuDpFXGUEiY1Kp0Y9mp9qh6u_e9XtRsBl3GinIS19HNMv4QQTrxt-LdKLZhJzCjjCFeDI5vDWK4Wcq_iNklbaZJehOWJBCjnBDCGlbQl_-gV2GJ5QcLxVuGIWspKRTaUzqGlKKxd8MgKNbExT5xURIXa-JiHeLF_VfcdfyJuADNHkhF8lsT7139X9dfX8a4Dw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1837407365</pqid></control><display><type>article</type><title>Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors</title><source>PubMed (Medline)</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Springer Nature OA Free Journals</source><creator>Falchook, Gerald S. ; Zhou, Xiaofei ; Venkatakrishnan, Karthik ; Kurzrock, Razelle ; Mahalingam, Devalingam ; Goldman, Jonathan W. ; Jung, JungAh ; Ullmann, Claudio Dansky ; Milch, Catherine ; Rosen, Lee S. ; Sarantopoulos, John</creator><creatorcontrib>Falchook, Gerald S. ; Zhou, Xiaofei ; Venkatakrishnan, Karthik ; Kurzrock, Razelle ; Mahalingam, Devalingam ; Goldman, Jonathan W. ; Jung, JungAh ; Ullmann, Claudio Dansky ; Milch, Catherine ; Rosen, Lee S. ; Sarantopoulos, John</creatorcontrib><description>Objective
This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Methods
Following overnight fasting for 10 h, a single 50 mg enteric-coated tablet (ECT) of alisertib was administered under either fasted (alisertib with 240 mL of water) or fed (high-fat meal consumed 30 min before receiving alisertib with 240 mL of water) conditions using a two-cycle, two-way crossover design. Patients on both arms were not allowed food for 4 h post-dose. Water was allowed as desired, except for 1 h before and after alisertib administration.
Results
Twenty-four patients were enrolled and 14 patients were PK-evaluable (ten patients were not PK-evaluable due to insufficient data). Following a single oral dose of alisertib, median
t
max
was 6 h and 3 h under fed and fasted conditions, respectively. The geometric mean ratio of AUC
inf
(fed- vs. fasted-state dosing) was 0.94 [90 % confidence interval (CI) 0.68–1.32]. The geometric mean
C
max
under fed conditions was 84 % of that under fasted conditions (90 % CI 66–106). Alisertib was generally well-tolerated; most common drug-related grade 3/4 adverse events included neutropenia (50 %), leukopenia (38 %), and thrombocytopenia (21 %).
Conclusions
Systemic exposures achieved following a single 50 mg dose of alisertib administered as an ECT formulation after a high-fat meal are similar to those observed in the fasted state. Alisertib 50 mg ECT can be administered without regard for food.
ClinicalTrials.gov Identifier
NCT00962091.</description><identifier>ISSN: 1174-5886</identifier><identifier>EISSN: 1179-6901</identifier><identifier>DOI: 10.1007/s40268-015-0114-8</identifier><identifier>PMID: 26689566</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject><![CDATA[Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Aurora Kinase A - antagonists & inhibitors ; Azepines - administration & dosage ; Azepines - pharmacokinetics ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Female ; Food-Drug Interactions ; Humans ; Internal Medicine ; Male ; Maximum Tolerated Dose ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Original ; Original Research Article ; Pharmacology/Toxicology ; Pharmacotherapy ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - pharmacokinetics ; Pyrimidines - administration & dosage ; Pyrimidines - pharmacokinetics]]></subject><ispartof>Drugs in R&D, 2016-03, Vol.16 (1), p.45-52</ispartof><rights>The Author(s) 2015</rights><rights>Drugs in R&D is a copyright of Springer, 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-1a4129a3e2c8ff00a6615baf5849cb2c84bb32cd18be1afbee6057acb4704a9b3</citedby><cites>FETCH-LOGICAL-c470t-1a4129a3e2c8ff00a6615baf5849cb2c84bb32cd18be1afbee6057acb4704a9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767718/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767718/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26689566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Falchook, Gerald S.</creatorcontrib><creatorcontrib>Zhou, Xiaofei</creatorcontrib><creatorcontrib>Venkatakrishnan, Karthik</creatorcontrib><creatorcontrib>Kurzrock, Razelle</creatorcontrib><creatorcontrib>Mahalingam, Devalingam</creatorcontrib><creatorcontrib>Goldman, Jonathan W.</creatorcontrib><creatorcontrib>Jung, JungAh</creatorcontrib><creatorcontrib>Ullmann, Claudio Dansky</creatorcontrib><creatorcontrib>Milch, Catherine</creatorcontrib><creatorcontrib>Rosen, Lee S.</creatorcontrib><creatorcontrib>Sarantopoulos, John</creatorcontrib><title>Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors</title><title>Drugs in R&D</title><addtitle>Drugs R D</addtitle><addtitle>Drugs R D</addtitle><description>Objective
This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Methods
Following overnight fasting for 10 h, a single 50 mg enteric-coated tablet (ECT) of alisertib was administered under either fasted (alisertib with 240 mL of water) or fed (high-fat meal consumed 30 min before receiving alisertib with 240 mL of water) conditions using a two-cycle, two-way crossover design. Patients on both arms were not allowed food for 4 h post-dose. Water was allowed as desired, except for 1 h before and after alisertib administration.
Results
Twenty-four patients were enrolled and 14 patients were PK-evaluable (ten patients were not PK-evaluable due to insufficient data). Following a single oral dose of alisertib, median
t
max
was 6 h and 3 h under fed and fasted conditions, respectively. The geometric mean ratio of AUC
inf
(fed- vs. fasted-state dosing) was 0.94 [90 % confidence interval (CI) 0.68–1.32]. The geometric mean
C
max
under fed conditions was 84 % of that under fasted conditions (90 % CI 66–106). Alisertib was generally well-tolerated; most common drug-related grade 3/4 adverse events included neutropenia (50 %), leukopenia (38 %), and thrombocytopenia (21 %).
Conclusions
Systemic exposures achieved following a single 50 mg dose of alisertib administered as an ECT formulation after a high-fat meal are similar to those observed in the fasted state. Alisertib 50 mg ECT can be administered without regard for food.
ClinicalTrials.gov Identifier
NCT00962091.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Aurora Kinase A - antagonists & inhibitors</subject><subject>Azepines - administration & dosage</subject><subject>Azepines - pharmacokinetics</subject><subject>Cross-Over Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Food-Drug Interactions</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Maximum Tolerated Dose</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Original</subject><subject>Original Research Article</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - pharmacokinetics</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - pharmacokinetics</subject><issn>1174-5886</issn><issn>1179-6901</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc9uFSEUxidGY2v1AdwYEjd1MQoz_JuNyaRptfGqTaxrAgzcoc5AC8w1voZPLOOtTTVxQSDn-52PA19VPUfwNYKQvUkYNpTXEJGyEK75g-oQIdbVtIPo4e8zrgnn9KB6ktIVhBC1lD-uDhpKeUcoPax-nlprdAbBgrMQBhA8yKMBF6OMs9Thm_MmO51Wfa2f-51J2W1ldsHLCfRLDFGCHnxwXqZVH51yOUTQTy6ZmJ0Cxx83n3jTslfAeXBROo3PCXx3eQT9sJNemwF8CZMbwOUyh5ieVo-snJJ5drsfVV_PTi9P3tebz-_OT_pNrTGDuUYSo6aTrWk0txZCSSkiSlrCcadVKWKl2kYPiCuDpFXGUEiY1Kp0Y9mp9qh6u_e9XtRsBl3GinIS19HNMv4QQTrxt-LdKLZhJzCjjCFeDI5vDWK4Wcq_iNklbaZJehOWJBCjnBDCGlbQl_-gV2GJ5QcLxVuGIWspKRTaUzqGlKKxd8MgKNbExT5xURIXa-JiHeLF_VfcdfyJuADNHkhF8lsT7139X9dfX8a4Dw</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Falchook, Gerald S.</creator><creator>Zhou, Xiaofei</creator><creator>Venkatakrishnan, Karthik</creator><creator>Kurzrock, Razelle</creator><creator>Mahalingam, Devalingam</creator><creator>Goldman, Jonathan W.</creator><creator>Jung, JungAh</creator><creator>Ullmann, Claudio Dansky</creator><creator>Milch, Catherine</creator><creator>Rosen, Lee S.</creator><creator>Sarantopoulos, John</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160301</creationdate><title>Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors</title><author>Falchook, Gerald S. ; Zhou, Xiaofei ; Venkatakrishnan, Karthik ; Kurzrock, Razelle ; Mahalingam, Devalingam ; Goldman, Jonathan W. ; Jung, JungAh ; Ullmann, Claudio Dansky ; Milch, Catherine ; Rosen, Lee S. ; Sarantopoulos, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-1a4129a3e2c8ff00a6615baf5849cb2c84bb32cd18be1afbee6057acb4704a9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Aurora Kinase A - antagonists & inhibitors</topic><topic>Azepines - administration & dosage</topic><topic>Azepines - pharmacokinetics</topic><topic>Cross-Over Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Food-Drug Interactions</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Maximum Tolerated Dose</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Original</topic><topic>Original Research Article</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - pharmacokinetics</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Falchook, Gerald S.</creatorcontrib><creatorcontrib>Zhou, Xiaofei</creatorcontrib><creatorcontrib>Venkatakrishnan, Karthik</creatorcontrib><creatorcontrib>Kurzrock, Razelle</creatorcontrib><creatorcontrib>Mahalingam, Devalingam</creatorcontrib><creatorcontrib>Goldman, Jonathan W.</creatorcontrib><creatorcontrib>Jung, JungAh</creatorcontrib><creatorcontrib>Ullmann, Claudio Dansky</creatorcontrib><creatorcontrib>Milch, Catherine</creatorcontrib><creatorcontrib>Rosen, Lee S.</creatorcontrib><creatorcontrib>Sarantopoulos, John</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drugs in R&D</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Falchook, Gerald S.</au><au>Zhou, Xiaofei</au><au>Venkatakrishnan, Karthik</au><au>Kurzrock, Razelle</au><au>Mahalingam, Devalingam</au><au>Goldman, Jonathan W.</au><au>Jung, JungAh</au><au>Ullmann, Claudio Dansky</au><au>Milch, Catherine</au><au>Rosen, Lee S.</au><au>Sarantopoulos, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors</atitle><jtitle>Drugs in R&D</jtitle><stitle>Drugs R D</stitle><addtitle>Drugs R D</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>45</spage><epage>52</epage><pages>45-52</pages><issn>1174-5886</issn><eissn>1179-6901</eissn><abstract>Objective
This study was conducted to characterize the effects of food on single-dose pharmacokinetics (PK) of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Methods
Following overnight fasting for 10 h, a single 50 mg enteric-coated tablet (ECT) of alisertib was administered under either fasted (alisertib with 240 mL of water) or fed (high-fat meal consumed 30 min before receiving alisertib with 240 mL of water) conditions using a two-cycle, two-way crossover design. Patients on both arms were not allowed food for 4 h post-dose. Water was allowed as desired, except for 1 h before and after alisertib administration.
Results
Twenty-four patients were enrolled and 14 patients were PK-evaluable (ten patients were not PK-evaluable due to insufficient data). Following a single oral dose of alisertib, median
t
max
was 6 h and 3 h under fed and fasted conditions, respectively. The geometric mean ratio of AUC
inf
(fed- vs. fasted-state dosing) was 0.94 [90 % confidence interval (CI) 0.68–1.32]. The geometric mean
C
max
under fed conditions was 84 % of that under fasted conditions (90 % CI 66–106). Alisertib was generally well-tolerated; most common drug-related grade 3/4 adverse events included neutropenia (50 %), leukopenia (38 %), and thrombocytopenia (21 %).
Conclusions
Systemic exposures achieved following a single 50 mg dose of alisertib administered as an ECT formulation after a high-fat meal are similar to those observed in the fasted state. Alisertib 50 mg ECT can be administered without regard for food.
ClinicalTrials.gov Identifier
NCT00962091.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26689566</pmid><doi>10.1007/s40268-015-0114-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1174-5886 |
ispartof | Drugs in R&D, 2016-03, Vol.16 (1), p.45-52 |
issn | 1174-5886 1179-6901 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4767718 |
source | PubMed (Medline); MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection; EZB Electronic Journals Library; Springer Nature OA Free Journals |
subjects | Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Aurora Kinase A - antagonists & inhibitors Azepines - administration & dosage Azepines - pharmacokinetics Cross-Over Studies Dose-Response Relationship, Drug Female Food-Drug Interactions Humans Internal Medicine Male Maximum Tolerated Dose Medicine Medicine & Public Health Middle Aged Neoplasms - drug therapy Neoplasms - metabolism Original Original Research Article Pharmacology/Toxicology Pharmacotherapy Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacokinetics Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics |
title | Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A32%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Food%20on%20the%20Pharmacokinetics%20of%20the%20Investigational%20Aurora%20A%20Kinase%20Inhibitor%20Alisertib%20(MLN8237)%20in%20Patients%20with%20Advanced%20Solid%20Tumors&rft.jtitle=Drugs%20in%20R&D&rft.au=Falchook,%20Gerald%20S.&rft.date=2016-03-01&rft.volume=16&rft.issue=1&rft.spage=45&rft.epage=52&rft.pages=45-52&rft.issn=1174-5886&rft.eissn=1179-6901&rft_id=info:doi/10.1007/s40268-015-0114-8&rft_dat=%3Cproquest_pubme%3E4243637001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1837407365&rft_id=info:pmid/26689566&rfr_iscdi=true |